Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial.

Citation data:

Journal of cardiac failure, ISSN: 1532-8414, Vol: 21, Issue: 2, Page: 153-9

Publication Year:
2015
Usage 76
Abstract Views 70
Link-outs 6
Captures 32
Readers 26
Exports-Saves 6
Citations 7
Citation Indexes 7
Repository URL:
http://researchbank.acu.edu.au/fhs_pub/5803
PMID:
25451704
DOI:
10.1016/j.cardfail.2014.10.016
Author(s):
Ueland, Thor; Aukrust, Pål; Nymo, Ståle H.; Kjekshus, John; McMurray, John J. V.; Wikstrand, John; Block, Dirk; Zaugg, Christian; Gullestad, Lars
Publisher(s):
Elsevier BV; Churchill Livingstone Inc.
Tags:
Medicine; heart failure; adverse outcome; extra cellular matrix; biglycan; mimecan; Cardiology
article description
The extracellular matrix (ECM) plays an important role in left ventricular remodeling and progression of heart failure (HF). Biglycan and mimecan are ECM proteins that are abundantly expressed in cardiac tissue but have not been evaluated as prognostic markers in HF. We investigated their interaction with statin treatment and association with adverse outcome in chronic HF.